Development of Pre-Erythrocytic Malaria Vaccines and antibodies

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications, trials & patents

Abstract

The major discovery this year are as follows. 1. Assessed the safety and efficacy L9LS is several Phase 2 clinical trials in Mali and Kenya in infants, young children and adults. 2. Demonstrated that affinity and cytolytic activity are the two major in vitro characteristics that predict in vivo protection by a monoclonal antibody against PfCSP 3. Demonstrated the role of Fc effector function for mediating protection in vivo by monoclonal antibodies against PfCSP 4. Developed multiple models to improve the potency of monoclonal antibodies against PfCSP. 5. Initiated development of a multi-stage vaccine against Pf. 6. Initiated two Phase 2 clinical trials in Kenya to assess safety and efficacy of L9LS in infants prior to vaccination and in the post-discharge setting. 7. Initiated a Phase 1/2 trial in Mali in infants to assess safety and efficacy of L9LS in a seasonal setting prior to R21 vaccination